{"title":"榄香烯促进多激酶抑制剂Lenvatinib和程序性死亡-1抑制剂Tislelizumab联合治疗晚期肝细胞癌的临床疗效","authors":"Jie Duan, Wei Chen, Changhao Chen, Fangnan Song, Faxi Chen, Fangfang Jiang, Huiwen Xing, Aidong Gu","doi":"10.37290/ctnr2641-452x.21:386-394","DOIUrl":null,"url":null,"abstract":"We have examined the effect of added elemene on the clinical efficacy of combined treatment of advanced hepatocellular carcinoma with lenvatinib and tislelizumab chemotherapy. Patients with advanced hepatocellular carcinoma (n = 150) were divided into groups of equal size and treated with the multi-kinase inhibitor lenvatinib plus the PD-1 inhibitor tislelizumab alone (control) or along with elemene (treatment), a plant sesquiterpene with antiproliferative effects. The results of the study show a higher objective response rate and local control rate, superior post-treatment liver function, immune function, anti-angiogenesis capacity, and better quality of life, as reflected by higher functional assessment of cancer therapy scores (P < 0.05). Additionally, after treatment, albumin and prealbumin were elevated, and patient-generated subjective global assessment scores declined in both groups after treatment, but no difference was found between the two groups (P > 0.05). To sum up, elemene added to lenvatinib and tislelizumab chemotherapy is effective in treating advanced hepatocellular carcinoma patients and is recommended for clinical use.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Elemene Promotes Clinical Efficacy of Multiple Kinase Inhibitor Lenvatinib and Programmed Death-1 Inhibitor Tislelizumab Combination in Advanced Hepatocellular Carcinoma\",\"authors\":\"Jie Duan, Wei Chen, Changhao Chen, Fangnan Song, Faxi Chen, Fangfang Jiang, Huiwen Xing, Aidong Gu\",\"doi\":\"10.37290/ctnr2641-452x.21:386-394\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We have examined the effect of added elemene on the clinical efficacy of combined treatment of advanced hepatocellular carcinoma with lenvatinib and tislelizumab chemotherapy. Patients with advanced hepatocellular carcinoma (n = 150) were divided into groups of equal size and treated with the multi-kinase inhibitor lenvatinib plus the PD-1 inhibitor tislelizumab alone (control) or along with elemene (treatment), a plant sesquiterpene with antiproliferative effects. The results of the study show a higher objective response rate and local control rate, superior post-treatment liver function, immune function, anti-angiogenesis capacity, and better quality of life, as reflected by higher functional assessment of cancer therapy scores (P < 0.05). Additionally, after treatment, albumin and prealbumin were elevated, and patient-generated subjective global assessment scores declined in both groups after treatment, but no difference was found between the two groups (P > 0.05). To sum up, elemene added to lenvatinib and tislelizumab chemotherapy is effective in treating advanced hepatocellular carcinoma patients and is recommended for clinical use.\",\"PeriodicalId\":10976,\"journal\":{\"name\":\"Current Topics in Nutraceutical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Topics in Nutraceutical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37290/ctnr2641-452x.21:386-394\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Topics in Nutraceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37290/ctnr2641-452x.21:386-394","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
Elemene Promotes Clinical Efficacy of Multiple Kinase Inhibitor Lenvatinib and Programmed Death-1 Inhibitor Tislelizumab Combination in Advanced Hepatocellular Carcinoma
We have examined the effect of added elemene on the clinical efficacy of combined treatment of advanced hepatocellular carcinoma with lenvatinib and tislelizumab chemotherapy. Patients with advanced hepatocellular carcinoma (n = 150) were divided into groups of equal size and treated with the multi-kinase inhibitor lenvatinib plus the PD-1 inhibitor tislelizumab alone (control) or along with elemene (treatment), a plant sesquiterpene with antiproliferative effects. The results of the study show a higher objective response rate and local control rate, superior post-treatment liver function, immune function, anti-angiogenesis capacity, and better quality of life, as reflected by higher functional assessment of cancer therapy scores (P < 0.05). Additionally, after treatment, albumin and prealbumin were elevated, and patient-generated subjective global assessment scores declined in both groups after treatment, but no difference was found between the two groups (P > 0.05). To sum up, elemene added to lenvatinib and tislelizumab chemotherapy is effective in treating advanced hepatocellular carcinoma patients and is recommended for clinical use.
期刊介绍:
Current Topics in Nutraceutical Research is an international, interdisciplinary broad-based peer reviewed scientific journal for critical evaluation of research on chemistry, biology and therapeutic applications of nutraceuticals and functional foods. The major goal of this journal is to provide peer reviewed unbiased scientific data to the decision makers in the nutraceutical and food industry to help make informed choices about development of new products.
To this end, the journal will publish two types of review articles. First, a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, a critical evaluation of current human experimental data to help market and deliver the product for medically proven use. This journal will also serve as a forum for nutritionists, internists, neurologists, psychiatrists, and all those interested in preventive medicine.
The common denominator of all of the topic to be covered by the journal must include nutraceuticals and/functional food. The following is an example of some specific areas that may be of interest to the journal. i) Role of vitamins, minerals, antioxidants and phytonutrients on cardiovascular health, cancer, diabetes, ocular health, mental health, men’s health, women’s health, infant nutrition, ii) Role of herbals on human health, iii) Dietary supplements and sleep, iv) Components of diet that may have beneficial effect on human health, v) regulation of apoptosis and cell viability, vi) Isolation and characterization of bioactive components from functional foods, vii) Nutritional genomics, and viii) Nutritional proteomics.